This article is more than 5 years old. Information may no longer be current.
EyeGate Pharma completes phase 2 study of transscleral drug delivery system
The EyeGate II ocular drug delivery system yielded positive results in a phase 2 clinical study for treatment of dry eye and anterior uveitis, the company announced at the joint meeting of the American Academy of Ophthalmology and the Pan-American Association of Ophthalmology.
EyeGate Pharma conducted the phase 2 study under an investigational new drug protocol approved by the U.S. Food and Drug Administration, according to materials provided by the company. The study included more than 100 patients with dry eye disease or anterior uveitis and 105 healthy controls.
"Results of the dry eye study showed significant findings in multiple symptoms and signs and had a rapid onset of action," EyeGate literature said. Results of the uveitis study are expected to be released during the fourth quarter.
The EyeGate II is designed to deliver a controlled dosage of an active compound, such as its lead internal clinical candidate, EGP-437 (dexamethasone phosphate ophthalmic solution).
The company's transscleral iontophoresis technology regulates each unit of medication delivered to the eye. The device's annular design and electrode composition use a low-voltage electrical current to safely and effectively deliver a wide array of medications, according to the company.
"EyeGate Pharma is the first company to demonstrate clinical significance utilizing iontophoresis for the local treatment of ocular conditions," the company said.